Although the European Medicines Agency (EMA) recently approved a recombinant FVIIa (rFVIIa) for the treatment of acute bleeding in postpartum hemorrhage (PPH), its use is associated with risks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback